The Latest Keratoconus Treatment Industry Statistics Explained
By 2027, the global Keratoconus treatment market is projected to reach USD 1.13 billion.
The statistic indicates that the global market for Keratoconus treatment is expected to grow significantly by the year 2027, reaching a projected value of USD 1.13 billion. This forecast suggests a growing demand for treatments related to Keratoconus, a progressive eye condition that causes the cornea to thin and bulge into a cone shape, leading to visual impairment. Factors contributing to this projected market expansion could include advancements in treatment technologies, increased awareness and diagnosis of Keratoconus, as well as a rising prevalence of the condition globally. With a substantial market value anticipated in the near future, stakeholders in the healthcare industry may need to prepare for heightened investment and innovation in Keratoconus treatment options.
The market size of Keratoconus Treatment in North America in 2020 was estimated to be USD 176.6 million.
The statistic ‘The market size of Keratoconus Treatment in North America in 2020 was estimated to be USD 176.6 million’ represents the total value of the market for products and services related to treating keratoconus, a progressive eye disorder characterized by thinning of the cornea and bulging of the eye. This figure indicates the amount of money spent on various treatments, medications, surgeries, and devices aimed at managing or correcting the condition within North America during the year 2020. The market size serves as a key indicator of the demand for keratoconus treatments in the region, reflecting the prevalence of the disease, advancements in treatment options, and overall healthcare spending related to this particular eye condition.
Asia Pacific, with 60% of the world population, is considered to be a high potential market for Keratoconus treatment.
The statistic that Asia Pacific, with 60% of the world population, is considered to be a high potential market for Keratoconus treatment highlights the significant market opportunity for addressing this eye condition in the region. With a large proportion of the global population residing in Asia Pacific, there is a substantial potential patient pool for keratoconus treatment. This statistic suggests that there is a considerable unmet need for effective treatment options for keratoconus in Asia Pacific, presenting a promising opportunity for healthcare providers, pharmaceutical companies, and other stakeholders to develop and introduce innovative solutions to cater to this market and improve the quality of life for individuals affected by keratoconus in the region.
The utilization rate of Corneal Cross-linking treatment for Keratoconus is expected to grow at a CAGR of 5.5% from 2021 to 2027.
The statistic indicates that the utilization rate of Corneal Cross-linking treatment for Keratoconus, a progressive eye disorder, is projected to increase at a compounded annual growth rate (CAGR) of 5.5% from the year 2021 to 2027. This growth rate signifies the anticipated average annual increase in the utilization of this specific treatment over the stated period. The expected rise in the utilization rate suggests a growing demand for Corneal Cross-linking therapy, likely driven by factors such as advancements in technology, increased awareness among clinicians and patients, and potentially improved access to healthcare services. This forecasted trend implies a positive outlook for the adoption of Corneal Cross-linking as a preferred treatment option for managing Keratoconus in the coming years.
In 2020, Contact Lenses segment accounted for the largest share, 57.8%, of the keratoconus treatment market.
In 2020, the Contact Lenses segment held the largest market share, representing 57.8% of the keratoconus treatment market. This statistic indicates that contact lenses are the most widely utilized treatment option for managing keratoconus, a condition characterized by the thinning and bulging of the cornea. Contact lenses are often prescribed to correct vision problems caused by keratoconus as they can help to improve visual acuity and provide comfort to individuals with this condition. The dominance of the Contact Lenses segment in the keratoconus treatment market suggests that this type of intervention is favored by both healthcare providers and patients due to its effectiveness and accessibility.
Women are more likely to go for corrective surgeries for keratoconus than men, as per industry stats.
The statistic that women are more likely to go for corrective surgeries for keratoconus than men, as per industry stats, suggests a gender discrepancy in the utilization of surgical interventions for treating keratoconus, a progressive eye disorder characterized by thinning and bulging of the cornea. This finding implies that there may be inherent or social factors that influence women to seek surgical solutions for their condition more frequently than men. Further investigation into possible reasons behind this gender disparity could provide valuable insights for healthcare providers in tailoring their services to better meet the needs of individuals affected by keratoconus, regardless of gender.
Corneal graft is expected to be used by almost 12-20% of the patients for treating Keratoconus by 2027.
This statistic indicates that by the year 2027, it is projected that approximately 12-20% of patients diagnosed with Keratoconus will undergo a corneal graft procedure as part of their treatment plan. Keratoconus is a progressive eye condition that causes the cornea to thin and change shape, leading to visual impairment. A corneal graft, also known as a corneal transplant, involves replacing part or all of the damaged cornea with healthy donor tissue to improve vision and restore corneal stability. The estimated range of 12-20% suggests variability in the number of patients opting for this surgical intervention, depending on factors such as disease progression, patient preferences, and advancements in medical technology.
Hospitals are the biggest end-users in Keratoconus treatment market accounting for 39.6% in 2020.
The statistic “Hospitals are the biggest end-users in the Keratoconus treatment market accounting for 39.6% in 2020” indicates that hospitals were the largest segment utilizing treatments for Keratoconus, a progressive eye condition that causes the cornea to thin and change shape. This suggests that hospitals play a significant role in providing care for individuals with Keratoconus, with nearly 40% of the market share attributed to their services. Hospital-based treatment may involve a range of interventions such as specialized contact lenses, corneal cross-linking, or even corneal transplant surgeries to manage the condition effectively. The high percentage of market share held by hospitals underscores their importance in delivering advanced medical care for individuals affected by Keratoconus.
In 2019, the U.S FDA approved the use of corneal cross-linking, a minimally invasive outpatient procedure for treating Keratoconus.
The statistic “In 2019, the U.S FDA approved the use of corneal cross-linking, a minimally invasive outpatient procedure for treating Keratoconus” indicates a significant development in the field of ophthalmology. Keratoconus is a progressive eye disorder that causes the cornea to thin and bulge into a cone-like shape, leading to distorted vision. Corneal cross-linking is a treatment that involves applying riboflavin (vitamin B2) eye drops to the cornea, followed by exposure to ultraviolet light. This process strengthens the collagen fibers in the cornea, stabilizing its shape and potentially preventing further deterioration of vision. With the FDA approval, this procedure became a viable option for patients in the United States, offering a minimally invasive and effective solution for managing Keratoconus.
In spite of potential complications, corneal transplantation has an overall success rate of over 90% in treating Keratoconus.
The statistic suggests that corneal transplantation is an effective treatment for Keratoconus despite the risks of potential complications. With an overall success rate exceeding 90%, this procedure has shown to be highly successful in improving the vision and quality of life for the majority of patients. Keratoconus is a progressive eye condition that causes the cornea to thin and bulge, leading to distorted vision. By replacing the damaged corneal tissue with a healthy donor cornea through transplantation, the surgery can correct the vision impairment and restore visual acuity. While there may be risks associated with the procedure, such as rejection or infection, the high success rate indicates that the benefits of corneal transplantation in treating Keratoconus outweigh the potential complications.
Over 50% of all keratoconus patients in Australia are diagnosed in their late teens or early twenties.
The statistic “Over 50% of all keratoconus patients in Australia are diagnosed in their late teens or early twenties” suggests that a significant portion of individuals with keratoconus in Australia start experiencing symptoms or are diagnosed with the condition during their late teenage years or early twenties. This indicates that keratoconus, a progressive eye disorder characterized by thinning and bulging of the cornea, commonly manifests itself in younger individuals in Australia. Early detection and diagnosis during this critical period could be important for timely management and intervention to potentially slow down the progression of the condition and preserve vision in these individuals.
The annual direct health care cost for keratoconus has been estimated to be USD 300 million in the United States.
The statistic states that the annual direct health care cost for keratoconus, a progressive eye disorder that results in a cone-shaped cornea, is estimated to be USD 300 million in the United States. This figure represents the total amount of money spent on medical services and treatments specifically related to managing and treating keratoconus on an annual basis. The cost includes expenses such as doctor visits, diagnostic tests, procedures, medications, and other healthcare services directly related to the condition. This statistic highlights the significant financial burden that keratoconus places on the healthcare system and individuals affected by the condition.
Major industry players for keratoconus treatment include CooperVision, Johnson & Johnson, and Bausch & Lomb Incorporated.
The statistic provided highlights the major industry players in the treatment of keratoconus, a progressive eye disease that causes the cornea to thin and bulge into a cone shape, leading to visual impairment. CooperVision, Johnson & Johnson, and Bausch & Lomb Incorporated are prominent companies known for their expertise and innovation in producing contact lenses and other specialized eyecare products for managing keratoconus. By being key players in this market, these companies contribute significantly to the research, development, and availability of advanced treatment options for individuals diagnosed with keratoconus, ultimately improving the quality of life for those affected by this condition.
The Intracorneal ring segment market for keratoconus treatment is expected to expand at the highest CAGR during the forecast period.
This statistic suggests that the market for intracorneal ring segments used in the treatment of keratoconus is projected to grow at the highest Compound Annual Growth Rate (CAGR) compared to other segments in the forecast period. Keratoconus is a progressive eye disease characterized by the thinning and bulging of the cornea, leading to visual distortion and impairment. Intracorneal ring segments are small, transparent devices surgically implanted into the cornea to reshape its curvature and improve vision for individuals with keratoconus. The expected high CAGR indicates a growing demand for this specific treatment option, possibly due to advancements in technology, increasing prevalence of keratoconus, or rising awareness among patients and healthcare providers about the effectiveness of intracorneal rings in managing the condition.
In the UNited States, the prevalence of keratoconus ranges from 1 in 375 to 1 in 2,000 persons.
The statistic stating that the prevalence of keratoconus in the United States ranges from 1 in 375 to 1 in 2,000 persons highlights the varying incidence rates of this ocular condition within the population. Keratoconus is a progressive eye disorder that affects the cornea, leading to its thinning and bulging into a cone-like shape. The range of prevalence suggests that approximately 200,000 to 800,000 individuals in the United States may be affected by keratoconus. Factors such as genetics, environment, and demographics may contribute to the differing rates of occurrence observed in various studies. Understanding the prevalence of keratoconus is crucial for healthcare planning, resource allocation, and raising awareness about this vision-threatening condition.
Proper contact lens fitting can preserve vision in mild to moderate keratoconus in 90% of the patients.
This statistic suggests that for individuals with mild to moderate keratoconus, ensuring that their contact lenses are properly fitted can lead to preserved vision in 90% of patients. Keratoconus is an eye condition characterized by the thinning and bulging of the cornea, leading to distorted vision. By custom-fitting contact lenses to the unique shape of the cornea in individuals with keratoconus, the vision can be corrected and maintained effectively. This statistic highlights the importance of seeking expert care and attention to detail in fitting contact lenses for individuals with mild to moderate keratoconus to optimize vision outcomes and ultimately preserve visual acuity for the majority of patients.
Approximately 10-20% of patients with Keratoconus may require surgical treatment.
The statistic that approximately 10-20% of patients with Keratoconus may require surgical treatment indicates the proportion of individuals with the progressive eye disorder who may need an intervention beyond non-invasive management. Keratoconus is a condition characterized by the thinning and bulging of the cornea, resulting in visual distortions and astigmatism. While many patients can manage their symptoms with glasses, contact lenses, or collagen cross-linking therapy, a subset of individuals may develop severe enough symptoms or corneal thinning that necessitates surgical procedures like corneal transplant or implantation of intracorneal rings to improve visual acuity and stabilize the cornea. Monitoring patients with Keratoconus for disease progression and considering surgical intervention when appropriate is crucial in managing this condition effectively.
On average, Keratoconus occurs 1.4:1 in the male to female ratio according to industry data.
This statistic indicates that, on average, there are 1.4 times more cases of Keratoconus diagnosed in males compared to females based on industry data. In other words, for every one female diagnosed with Keratoconus, there are 1.4 males diagnosed with the condition. This male-to-female ratio suggests a slightly higher prevalence or likelihood of developing Keratoconus among males as opposed to females. Understanding such gender differences in disease prevalence can be important for healthcare professionals in terms of early detection, diagnosis, and treatment strategies tailored to the specific needs of each gender group.
References
0. – https://www.www.aoa.org
1. – https://www.www.ncbi.nlm.nih.gov
2. – https://www.www.jotform.com
3. – https://www.www.keratoconusgroup.org
4. – https://www.www.reviewofoptometry.com
5. – https://www.www.alliedmarketresearch.com
6. – https://www.www.aao.org
7. – https://www.www.transparencymarketresearch.com
8. – https://www.www.grandviewresearch.com
9. – https://www.www.prnewswire.com
10. – https://www.www.fortunebusinessinsights.com
11. – https://www.www.keratoconus.asn.au
